Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management highlighting commercial momentum in both established and emerging product areas. CEO Reshma Kewalramani pointed to "strong revenue growth as we reach more patients with more products," emphasizing milestone achievements for AlifTrack, KASJEVY, and Gernavix. The company also attributed performance to broader label eligibility and successful international expansion, particularly for its cystic fibrosis therapies. Management cited robust operational execution in research and development, including rapid regulatory submissions and advancement of late-stage clinical programs.

Is now the time to buy VRTX? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call

• Jessica Fye (JPMorgan): asked about the potential for the renal franchise to rival cystic fibrosis in size. CEO Reshma Kewalramani detailed the significant patient populations for Vertex’s renal assets and highlighted Povi as the near-term focus due to strong clinical data.
• Salveen Richter (Goldman Sachs): inquired about data read-through from a competitor’s program to Vertex’s enaxaplin. Kewalramani emphasized Vertex’s trial design and noted that results from the separate AMPLIFIED study are expected later this year.
• Brian Abrahams (RBC Capital Markets): questioned how Vertex would differentiate Povi for physicians given existing competition. Chief Commercial Officer Duncan McKechnie stressed Povi’s unique clinical profile, monthly dosing, and supportive infrastructure for rapid reimbursement and patient access.
• David Risinger (Leerink Partners): asked about Gernavix revenue reconciliation and formulary coverage. McKechnie explained that Q1 revenue reflected inventory dynamics and that payer coverage is expanding, which should accelerate revenue as gross-to-net normalizes.
• Evan Seigerman (BMO): sought more detail on the VX-522 discontinuation and future plans for hard-to-treat cystic fibrosis patients. Kewalramani reported that tolerability issues were linked to delivery technology and said Vertex would explore alternative modalities for these patients.

Catalysts in Upcoming Quarters

Over the coming quarters, our analysts will focus on (1) the pace of adoption for KASJEVY and Gernavix as broader payer coverage and increased field force support drive prescriptions, (2) the regulatory progress and commercial launch preparations for povitacicept in IgA nephropathy, and (3) continued expansion of cystic fibrosis therapies into younger age groups and new geographies. Progress in the nephrology pipeline and results from key clinical studies will also be important markers to watch.

Vertex Pharmaceuticals currently trades at $428.50, in line with $429.85 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

The Best Stocks for High-Quality Investors

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.